摘要
目的通过检测肽酰基精氨酸脱亚胺酶4(PAD4)在ANCA相关性小血管炎(AAV)患者血清中的水平,探讨其在AAV发病中的作用及意义。方法收集13例AAV患者发作期与缓解期血清,11例原发性慢性肾脏病患者的血清,12例健康对照的血清。用酶联免疫吸附法(ELISA)检测PAD4的水平,分析其与AAV患者BVAS评分的关系。结果(1)在AAV组,PAD4在发作期与缓解期的水平明显高于健康对照组;而在慢性肾脏病患者组中,PAD4水平与健康对照相比无显著差异。(2)AAV组有肾损害的患者PAD4水平,无论发作期还是缓解期,均高于慢性肾脏病组患者的PAD4水平。(3)AAV肾损害组患者发作期的PAD4水平与BVAS评分呈显著正相关(r=0.71,P=0.02)。结论PAD4参与了AAV的发生和发展。
Objective To explore the significance of peptidylarginine deiminase type 4 (PAD4) in the pathogenesis of ANCA-associated vasculitis (AAV) by detecting its level in patients with AAV. Methods Sera from 13 patients with AAV, 11 patients with primary chronic kidney disease and 12 healthy controls were collected. Serum PAD4 was detected using commercial ELISA kits. The association between serum PAD4 and BVAS of AAV was further investigated. Results (1) The serum level of PAD4 in patients with AAV in active and remission stages were all higher than that in the healthy controls. The serum level of PAD4 in patients with CKD was not found elevated compared with the normal controls. (2) The serum levels of PAD4 in AAV with renal damage were all significantly higher than that in CKD group no matter in active or remission stage. (3) The serum level of PAD4 in AAV with renal damage in active stage was positively correlated with BVAS (r = 0.71, P= 0.02). Conclusion PAD4 is involved in the pathogenesis of AAV.
出处
《中华肾脏病杂志》
CAS
CSCD
北大核心
2014年第5期327-331,共5页
Chinese Journal of Nephrology